Oncocross Co., Ltd. (KOSDAQ:382150)

Oncocross Statistics

Total Valuation

Oncocross has a market cap or net worth of KRW 94.52 billion. The enterprise value is 76.45 billion.

Market Cap	94.52B
Enterprise Value	76.45B

Important Dates

The last earnings date was Friday, April 3, 2026.

Earnings Date	Apr 3, 2026
Ex-Dividend Date	n/a

Share Statistics

Oncocross has 12.20 million shares outstanding. The number of shares has increased by 14.12% in one year.

Current Share Class	12.20M
Shares Outstanding	12.20M
Shares Change (YoY)	+14.12%
Shares Change (QoQ)	-0.01%
Owned by Insiders (%)	25.30%
Owned by Institutions (%)	10.87%
Float	6.96M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	255.14
PB Ratio	7.07
P/TBV Ratio	7.09
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-8.56
EV / Sales	206.35
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.14

Financial Position

The company has a current ratio of 4.21, with a Debt / Equity ratio of 0.40.

Current Ratio	4.21
Quick Ratio	4.11
Debt / Equity	0.40
Debt / EBITDA	n/a
Debt / FCF	-0.50
Interest Coverage	-16.77

Financial Efficiency

Return on equity (ROE) is -52.79% and return on invested capital (ROIC) is -27.77%.

Return on Equity (ROE)	-52.79%
Return on Assets (ROA)	-21.43%
Return on Invested Capital (ROIC)	-27.77%
Return on Capital Employed (ROCE)	-38.05%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -30.62% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-30.62%
50-Day Moving Average	7,769.60
200-Day Moving Average	9,662.80
Relative Strength Index (RSI)	55.73
Average Volume (20 Days)	723,754

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncocross had revenue of KRW 370.46 million and -8.93 billion in losses. Loss per share was -747.00.

Revenue	370.46M
Gross Profit	339.24M
Operating Income	-8.83B
Pretax Income	-8.93B
Net Income	-8.93B
EBITDA	-8.02B
EBIT	-8.83B
Loss Per Share	-747.00

Balance Sheet

The company has 23.43 billion in cash and 5.36 billion in debt, with a net cash position of 18.07 billion or 1,481.88 per share.

Cash & Cash Equivalents	23.43B
Total Debt	5.36B
Net Cash	18.07B
Net Cash Per Share	1,481.88
Equity (Book Value)	13.37B
Book Value Per Share	1,113.78
Working Capital	18.46B

Cash Flow

In the last 12 months, operating cash flow was -7.41 billion and capital expenditures -3.30 billion, giving a free cash flow of -10.70 billion.

Operating Cash Flow	-7.41B
Capital Expenditures	-3.30B
Depreciation & Amortization	809.92M
Net Borrowing	12.18B
Free Cash Flow	-10.70B
FCF Per Share	-877.50

Margins

Gross Margin	91.57%
Operating Margin	-2,383.02%
Pretax Margin	-2,410.17%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncocross does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-14.12%
Shareholder Yield	-14.12%
Earnings Yield	-9.45%
FCF Yield	-11.32%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Oncocross has an Altman Z-Score of 1.9 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.9
Piotroski F-Score	1